GNTA (Genenta Science SPA) Beta: 0.3792 (As of Jul. 08, 2026)


GNTA Genenta Science SPA GNTA
31 GF Score
Price $1.53
! 4 Warning Signs
View Full Analysis

What is Genenta Science SPA Beta?

Genenta Science SPA GNTA -5.26% 31 Beta is 0.3792 as of Jul. 08, 2026. GuruFocus rates GNTA with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-08), Genenta Science SPA's Beta is 0.3792.

Genenta Science SPA  (NAS:GNTA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Genenta Science SPA Beta Related Terms

Genenta Science SPA Beta Historical Data

* Premium members only.

The historical data trend for Genenta Science SPA's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genenta Science SPA Beta Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.78 -0.01

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.78 0.15 -0.01

GNTA vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Genenta Science SPA's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genenta Science SPA Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's Beta distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's Beta falls into.


GNTA
31GF Score
Genenta Science SPA GNTA
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genenta Science SPA Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3792 mean?
Genenta Science SPA (GNTA) has a Beta of 0.3792 as of Jul. 08, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Genenta Science SPA and its competitors.
Is Genenta Science SPA's Beta too high?
Genenta Science SPA's current Beta is 0.3792. Overall, Genenta Science SPA has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Genenta Science SPA's Beta compare to VRTX and REGN?
Genenta Science SPA's Beta of 0.3792 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Genenta Science SPA and its competitors. Genenta Science SPA's current Beta is 0.3792. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genenta Science SPA stock overvalued right now?
Genenta Science SPA (GNTA) has a current Beta of 0.3792. The current Beta is 0.3792. Genenta Science SPA's overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Genenta Science SPA (GNTA), the current Beta is 0.3792 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genenta Science SPA Business Description

Other Exchanges K5F:Germany
Address Via dell’Annunciata No. 31, Milan, ITA, 20121
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
31GF Score

Get the complete analysis for GNTA

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.53
Price